Formulation and Development of Medicated Chewing Gum Containing Ondansetron and Domperidone

Abstract

This study aimed to determine the feasibility of combining ondansetron and domperidone into a single medicated gum. Molded Chewing Gum (MCG) was developed via direct compression. Our medicated chewing gum was designed with diabetics in mind, and Stevia was selected for the research because it does not increase blood glucose levels. Direct compression was used in the development of medicated gum. Each formulation's permissible flow characteristics and pre-compression parameters, including bulk density, tapered density, Carr's compressibility index, and Hausner ratio, were shown. After compression, it was determined that all of the parameters were within acceptable limits, including changes in weight, thickness, appearance, and in vitro drug release. There is no indication of drug-excipient interactions based on physical testing or TLC analysis. Two plasticizers only when comparing glycerol with coconut oil, the latter proved to be the superior plasticizer. Formulation F6 was chosen as the best option since all of the attributes fall within the expected range. The results of the F6 formulation were analyzed for their thickness, weight fluctuation, appearance, and in vitro drug release. Coconut oil shown to be the superior plasticizer for making MCG after testing and evaluation. Probably because the concentration is optimized for releasing the drug from the formulation, the fact that F6 includes 24 mg of coconut oil makes it a more effective formulation.